NICOLE ROSS: Open Payments
NPI 1790057677 · PHILADELPHIA, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$5,508 in 28 payments from 7 companies in 2025. Trend: 2023 $47 · 2024 $4,463 · 2025 $5,508
Speaker / faculty: $3,570Food & beverage: $1,038Travel & lodging: $900
| Company | Payments | Amount |
|---|---|---|
| Exelixis Inc. | 18 | $5,065 |
| REVANCE THERAPEUTICS, INC. | 5 | $218 |
| Astellas Pharma US Inc | 1 | $122 |
| Gilead Sciences, Inc. | 1 | $38 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $26 |
| Ipsen Biopharmaceuticals, Inc | 1 | $25 |
| Pharmacosmos Therapeutics Inc. | 1 | $14 |
Products named: CABOMETYX, DAXXIFY, Vyloy, FRUZAQLA, Somatuline Depot, MONOFERRIC.
Industry payments across PA — which companies pay providers there.
